Agile Therapeutics (NSDQ:AGRX) touted data today from a Phase III trial of its once-weekly, low-dose hormonal contraceptive patch, Twirla. The study showed that women experienced mean decreases in length of bleeding and spotting episodes, the Princeton, N.J.-based company reported. Get the full story at our sister site, Drug Delivery Business News.
Drug-Device Combinations
TCT 2017: OrbusNeich’s dual therapy stent non-inferior to Abbott’s Xience DES in 1-year follow-up
OrbusNeich touted results today from a pivotal registration study comparing its Combo dual therapy stent with Abbott’s (NYSE:ABT) Xience stent in patients with ischemic heart disease. The trial is designed to evaluate the effectiveness of OrbusNeich’s combined endothelial progenitor cell capture and drug-eluting stent. The data showed that the device is non-inferior to Abbott’s drug-eluting stent after […]
Elixir Medical unveils ‘bioadaptive’ metallic drug-eluting stent at TCT 2017
Interventional cardiologists have used stents to keep the heart’s coronary arteries open for decades. Transitioning from bare-metal stents to drug-eluting stents in the early 2000s brought tremendous benefits for patients. “But over the last 10 years, the technological progress and meaningful clinical improvements have plateaued,” Elixir Medical CEO Motasim Sirhan told Drug Delivery Business News. “When you stent an artery today, you […]
TCT 2017: Abbott’s Xience coronary stent helps patients feel better faster than open-heart surgery
Abbott (NYSE:ABT) reported today that patients who were treated with the company’s Xience coronary stent for left-main coronary artery disease felt better faster compared to patients who had open-heart surgery, so at the end choosing the right Doctors Surgery is essential. The data were presented at this year’s Transcatheter Cardiovascular Therapeutics meeting during a late-breaking session. […]
Cordis inks exclusive distribution deal for Medinol’s coronary stent portfolio in US
Cordis has inked an exclusive distribution deal to sell Medinol‘s coronary stents in the U.S., the company reported, adding a cobalt-chromium bare-metal stent and a drug-eluting stent to its portfolio. According to the deal, Cordis plans to start selling Medinol’s NIRxcell BMS immediately and will exclusively distribute the company’s EluNir drug-eluting stent if it wins FDA approval. […]
Allergan’s intravitreal implant wins approval in China
Allergan (NYSE:AGN) said today that it landed an imported drugs license from the Chinese FDA to market its dexamethasone intravitreal implant, Ozurdex, as a treatment for adults with macular edema following branch retinal vein occlusion or central retinal vein occlusion. The Dublin-based pharma giant touted its therapy as the first intravitreal injection approved for RVO in […]
Tandem reels in losses but misses revenue estimates in Q3
Shares in Tandem Diabetes Care (NSDQ:TNDM) rose today after the medical device maker reeled in its losses but missed sales estimates on Wall Street with its third quarter results. The San Diego, Calif.-based company posted losses of -$16 million on sales of $23.7 million for the 3 months ended Sept. 30, for bottom-line growth of 46% on […]
Merck raises full-year guidance despite mixed Q3
Shares in Merck (NYSE:MRK) slipped in pre-market activity today after the pharmaceutical company beat earnings estimates but missed sales expectations on Wall Street with its third quarter results. The Kenilworth, N.J.-based company posted a loss of -$51 million, or -2¢ per share, on sales of $10.33 billion for the 3 months ended Sept. 30. Get the full […]
Medinol wins CE Mark for EluNir drug-eluting coronary stent system
Medinol said today that it won CE Mark clearance for its EluNir drug-eluting stent – a device designed with a low metal footprint and a elastomeric coating. In one 958-patient clinical study, the coronary stent had a 12-month target lesion failure rate of 5.4% and a 0% rate of late stent thrombosis, proving non-inferior to the […]
Meet 5 companies developing novel drug-delivery devices
At the 7th annual Partnership Opportunities in Drug Delivery event, presented by The Conference Forum, device companies gathered to tout their drug-delivery technologies and learn from each other’s mistakes and successes. Among them were needle-free injectors, patch pumps, auto-injectors and other novel delivery devices. Moderated by Pfizer‘s (NYSE:PFE) senior director of device strategy, Mathias Romacker, companies including Insulet (NSDQ:PODD), West Pharmaceutical […]
West Pharma posts Street-beating Q3 earnings, sales
Shares in West Pharmaceutical Services (NYSE:WST) rose today after the company beat expectations on Wall Street with its third quarter results. The Exton, Penn.-based company posted profits of $51 million, or 69¢ per share, on sales of $398.2 million for the 3 months ended Sept. 30, for bottom-line growth of 36% on sales growth of 6% compared […]